BiotechTube
Home/Pipeline/TPQD

TPQD

Not Specified

Pre-clinicalActive

Key Facts

Indication
Not Specified
Phase
Pre-clinical
Status
Active
Company
RLS Therapeutics

About RLS Therapeutics

RLS Therapeutics is an early-stage, private biotech leveraging a proprietary small molecule platform to develop therapeutics for broad disease applications. The company emphasizes a mechanism-driven approach to improve efficacy over current symptom-management treatments and is actively seeking investment and partnership to advance its pipeline. Led by an experienced team and advisory board, RLS is in a pre-clinical/pre-revenue stage, with its lead compound, TPQD, highlighted as a development candidate.

View full company profile

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved